THERAPEUTIC EMBRYO GENE-CORRECTION LAW IN RUSSIA

1. INTRODUCTION

Therapeutic embryo gene correction refers to the proposed use of genetic technologies to correct disease-associated genetic abnormalities in human embryos. Its objective is to prevent the transmission of serious hereditary disorders and potentially reduce the incidence of genetic diseases in future generations.

In Russia, this subject raises significant legal questions concerning reproductive rights, embryo protection, biomedical research, human dignity, genetic privacy, medical consent and the limits of genetic modification.

An important legal distinction must be made between somatic gene therapy, which affects an individual patient without intentionally modifying future generations, and germline or embryo gene editing, which may produce heritable genetic changes.

Russia does not have a comprehensive statutory approval framework authorising clinical reproductive use of gene-corrected human embryos. Existing legislation governing assisted reproduction, biomedical research and genetic information must therefore be considered alongside restrictions and unresolved questions concerning heritable genome modification.

2. PRINCIPAL LEGAL AND REGULATORY FRAMEWORK

A. FEDERAL LAW NO. 323-FZ ON THE FUNDAMENTALS OF HEALTH PROTECTION OF CITIZENS (2011)

This legislation establishes the principal legal framework for healthcare and medical activities in Russia.

Its provisions concerning medical intervention, informed voluntary consent, medical confidentiality and reproductive healthcare are relevant to embryo-related medical research.

Medical interventions must comply with applicable legal requirements and professional standards. However, general provisions permitting medical treatment do not automatically authorise reproductive germline modification.

B. FEDERAL LAW NO. 180-FZ ON BIOMEDICAL CELLULAR PRODUCTS (2016)

This legislation regulates the development, production and circulation of specified biomedical cellular products.

It may be relevant to certain cellular biotechnology applications, but it does not constitute a general authorisation for therapeutic genetic correction of human embryos.

C. FEDERAL LAW NO. 152-FZ ON PERSONAL DATA (2006)

This legislation regulates the processing of personal information, including genetic information where it relates to identifiable individuals.

Genetic information may receive heightened protection as information concerning health or other specially protected personal information, depending on the processing context.

Research organisations must establish lawful grounds for processing genetic data and comply with applicable consent, security and confidentiality requirements.

D. FEDERAL LAW NO. 149-FZ ON INFORMATION, INFORMATION TECHNOLOGIES AND INFORMATION PROTECTION (2006)

This legislation establishes general requirements for information protection and information-system governance.

It becomes relevant where embryo research institutions maintain genetic databases, digital laboratory records or electronic reproductive-health information.

E. FEDERAL LAW NO. 86-FZ ON STATE REGULATION IN THE FIELD OF GENETIC ENGINEERING ACTIVITIES (1996)

This legislation provides a regulatory framework for specified genetic-engineering activities.

Its relevance to human embryo modification must be distinguished from its provisions concerning genetically engineered organisms and other regulated activities. It should not be interpreted as independently granting permission for clinical human germline editing.

3. REGULATION OF ASSISTED REPRODUCTIVE TECHNOLOGIES

Russian reproductive healthcare is governed by Federal Law No. 323-FZ and associated implementing regulations.

Assisted reproductive technologies include in-vitro fertilisation and other medically recognised reproductive procedures.

The regulatory framework addresses:

Medical indications for assisted reproduction.

Informed consent of individuals undergoing reproductive treatment.

Medical confidentiality.

Rights and responsibilities of healthcare institutions.

Requirements concerning reproductive medical services.

Protection of patients and relevant reproductive materials.

Embryo creation and storage within legally recognised assisted-reproduction procedures must be distinguished from genetic modification intended to produce heritable changes.

The legal availability of IVF does not automatically establish the legality of modifying an embryo's heritable genome.

4. LEGAL STATUS OF THERAPEUTIC EMBRYO GENE CORRECTION

Therapeutic embryo gene correction raises several unresolved legal questions.

A. HERITABLE GENETIC MODIFICATION

Changes introduced into reproductive cells or embryos may be inherited by subsequent generations.

This creates legal concerns involving the rights and interests of future children, long-term safety and intergenerational consequences.

B. MEDICAL NECESSITY

The distinction between preventing a serious hereditary disease and introducing non-medical genetic characteristics is important.

A proposed therapeutic objective does not, by itself, establish that the intervention is legally authorised.

C. EMBRYO PROTECTION

Embryo-related research must be assessed under applicable reproductive-healthcare rules, medical ethics requirements and institutional research oversight.

D. INFORMED CONSENT

Parents or prospective parents cannot automatically provide unlimited consent to every possible future genetic intervention.

Consent must comply with applicable legislation and research-ethics requirements.

E. CLINICAL RESPONSIBILITY

Healthcare institutions and researchers may face civil, administrative or criminal liability where unlawful or negligent conduct causes harm.

5. BIOETHICAL AND INTERNATIONAL LEGAL CONSIDERATIONS

Russia's regulatory position must also be understood in the context of international bioethics.

Important reference instruments include:

UNESCO Universal Declaration on the Human Genome and Human Rights (1997).

UNESCO International Declaration on Human Genetic Data (2003).

Council of Europe Convention on Human Rights and Biomedicine, commonly known as the Oviedo Convention (1997).

Article 13 of the Oviedo Convention restricts interventions seeking to modify the human genome to preventive, diagnostic or therapeutic purposes, subject to the additional requirement that the intervention must not aim to introduce modifications in the genome of descendants.

Important Russian qualification: Russia signed the Oviedo Convention in 2001 but has not ratified it. Consequently, it should not be presented as a directly binding treaty obligation for Russia.

The UNESCO declarations provide important ethical guidance but are not equivalent to binding domestic legislation.

6. INTELLECTUAL PROPERTY AND COMMERCIALISATION

Therapeutic embryo gene-correction research may involve patents, genetic technologies, laboratory equipment, diagnostic systems and biotechnology licensing agreements.

Part IV of the Russian Civil Code governs intellectual property rights.

Relevant legal considerations include:

Ownership of research inventions.

Licensing of biotechnology patents.

Protection of confidential research information.

Ownership of laboratory-developed software.

Commercial research agreements.

Restrictions arising from applicable public-policy and regulatory requirements.

The existence of patent protection does not independently establish permission to conduct clinical embryo gene-editing procedures.

7. IMPORTANT JUDICIAL PRECEDENTS

There is no established body of Russian Supreme Court or Constitutional Court judgments directly authorising therapeutic human embryo gene correction. The following cases provide relevant general or comparative legal principles.

1. European Court of Human Rights, Evans v. United Kingdom (2007)

The Court considered disputes involving stored embryos and reproductive autonomy. It examined the competing rights and interests of individuals involved in assisted reproduction.

Relevance: This judgment provides comparative guidance concerning embryo-related consent, reproductive autonomy and the legal consequences of disagreements concerning stored embryos.

2. European Court of Human Rights, Parrillo v. Italy (2015)

The Court examined the legal treatment of embryos created through assisted reproduction and the restrictions on their use for scientific research.

Relevance: The decision is relevant to the relationship between reproductive autonomy, embryo research and state regulation.

3. European Court of Human Rights, Costa and Pavan v. Italy (2012)

The Court considered restrictions on access to preimplantation genetic diagnosis for prospective parents carrying hereditary diseases.

Relevance: This decision is important for understanding the relationship between reproductive rights, genetic disease prevention and access to assisted reproductive technologies.

4. European Court of Human Rights, S.H. and Others v. Austria (2011)

The Court examined restrictions on assisted reproductive technologies and the state's regulatory discretion in reproductive medicine.

Relevance: Its reasoning is relevant to the regulation of innovative reproductive technologies and the balance between individual autonomy and public interests.

5. European Court of Human Rights, Vo v. France (2004)

The Court examined the legal protection of unborn life and recognised the absence of a uniform European legal definition of when legal personality begins.

Relevance: This judgment provides comparative guidance concerning the legal status and protection of embryos and unborn life.

6. European Court of Human Rights, A, B and C v. Ireland (2010)

The Court examined reproductive autonomy and the relationship between individual rights and domestic regulation of reproductive matters.

Relevance: Its broader principles may inform discussions about reproductive decision-making and the limits of state intervention.

These are comparative European human-rights authorities, not binding Russian judgments establishing a right to perform embryo gene correction. Their applicability to Russian legal questions must also account for Russia's departure from the European Convention on Human Rights, effective 16 September 2022.

8. REGULATORY COMPLIANCE AND INSTITUTIONAL RESPONSIBILITIES

Russian healthcare institutions and biotechnology research organisations should consider the following compliance requirements:

Establish whether the proposed activity falls within an authorised category of medical or scientific research.

Obtain necessary institutional and regulatory approvals.

Ensure that research participants receive legally adequate information and provide valid consent.

Protect identifiable genetic and reproductive-health information.

Maintain research records and medical confidentiality.

Establish independent ethical review where required.

Assess applicable intellectual property and licensing restrictions.

Ensure that research activities do not exceed the scope of legally authorised procedures.

Examine potential civil, administrative and criminal liability.

Research approval, ethical approval and clinical authorisation are separate legal considerations and should not be treated as interchangeable.

9. CONCLUSION

Therapeutic embryo gene correction in Russia occupies a legally sensitive area involving reproductive medicine, genetic engineering, biomedical research, human rights and bioethics. Federal Law No. 323-FZ, Federal Law No. 152-FZ and related legislation provide important elements of the applicable regulatory framework. However, these laws do not collectively establish a general authorisation for clinical heritable human embryo gene editing. Comparative judicial decisions concerning reproductive autonomy, embryo research and genetic disease prevention provide useful interpretative guidance but do not create a direct legal permission under Russian law. A comprehensive regulatory approach would require clear legislative provisions addressing clinical authorisation, embryo protection, long-term responsibility, consent, genetic privacy and intergenerational risks.